Abstract

Heterotypic amyloid interactions between related protein sequences have been observed in functional and disease amyloids. While sequence homology seems to favour heterotypic amyloid interactions, we have no systematic understanding of the structural rules determining such interactions nor whether they inhibit or facilitate amyloid assembly. Using structure-based thermodynamic calculations and extensive experimental validation, we performed a comprehensive exploration of the defining role of sequence promiscuity in amyloid interactions. Using tau as a model system we demonstrate that proteins with local sequence homology to tau amyloid nucleating regions can modify fibril nucleation, morphology, assembly and spreading of aggregates in cultured cells. Depending on the type of mutation such interactions inhibit or promote aggregation in a manner that can be predicted from structure. We find that these heterotypic amyloid interactions can result in the subcellular mis-localisation of these proteins. Moreover, equilibrium studies indicate that the critical concentration of aggregation is altered by heterotypic interactions. Our findings suggest a structural mechanism by which the proteomic background can modulate the aggregation propensity of amyloidogenic proteins and we discuss how such sequence-specific proteostatic perturbations could contribute to the selective cellular susceptibility of amyloid disease progression.

In this work, Louros et al. uncover a rule book for interactions of amyloids with other proteins. This grammar was shown to promote cellular spreading of tau aggregates in cells, but can also be harvested to develop structure-based aggregation blockers.

Details

Title
Mapping the sequence specificity of heterotypic amyloid interactions enables the identification of aggregation modifiers
Author
Louros Nikolaos 1   VIAFID ORCID Logo  ; Meine, Ramakers 1 ; Michiels Emiel 1 ; Konstantoulea Katerina 1   VIAFID ORCID Logo  ; Morelli Chiara 1 ; Garcia, Teresa 1 ; Moonen Nele 1 ; D’Haeyer Sam 2   VIAFID ORCID Logo  ; Goossens, Vera 2 ; Thal, Dietmar Rudolf 3   VIAFID ORCID Logo  ; Audenaert, Dominique 2 ; Rousseau, Frederic 1   VIAFID ORCID Logo  ; Schymkowitz Joost 1   VIAFID ORCID Logo 

 Switch Laboratory, VIB Center for Brain and Disease Research, Leuven, Belgium (GRID:grid.511015.1); KU Leuven, Switch Laboratory, Department of Cellular and Molecular Medicine, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 VIB Screening Core, Ghent, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Ghent University, Centre for Bioassay Development and Screening (C-BIOS), Ghent, Belgium (GRID:grid.5342.0) (ISNI:0000 0001 2069 7798) 
 KU Leuven, Leuven Brain Institute, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Laboratory for Neuropathology, KU Leuven, and Department of Pathology, UZ Leuven, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2639132159
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.